Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10373321" target="_blank" >RIV/00216208:11110/18:10373321 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1111/apt.14539" target="_blank" >https://doi.org/10.1111/apt.14539</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/apt.14539" target="_blank" >10.1111/apt.14539</a>
Alternative languages
Result language
angličtina
Original language name
Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus
Original language description
In 2013, a systematic review and Delphi consensus reported that specific probiotics can benefit adult patients with irritable bowel syndrome (IBS) and other gastrointestinal (GI) problems. To update the consensus with new evidence. A systematic review identified randomised, placebo-controlled trials published between January 2012 and June 2017. Evidence was graded, previosly developed statements were reassessed by an 8-expert panel, and agreement was reached via Delphi consensus. A total of 70 studies were included (IBS, 34; diarrhoea ssociated with antibiotics, 13; diarrhoea associated with Helicobacter pylori eradication therapy, 7; other conditions, 16). Of 15 studies that examined global IBS symptoms as a primary endpoint, 8 reported significant benefits of probiotics vs placebo. Consensus statements with 100% agreement and "high" evidence level indicated that specific probiotics help reduce overall symptom burden and abdominal pain in some patients with IBS and duration/intensity of diarrhoea in patients prescribed antibiotic or H. pylori eradication therapy, and have favourable safety. Statements with 70%-100% agreement and "moderate" evidentce indicated that, in some patients with IBS, specific probiotics help reduce bloating/distension and improve bowel movement frequency/consistency. This updated review indicates that specific probiotics are beneficial in certain lower GI problems, although many of the new publication did not report benefits of probiotic, possibly due to inclusion of new, less efficacious preparations. Specific probiotics can relieve lower GI symptoms in IBS, prevent diarrhoea associated with antibiotics and H. pylori eradication therapy, and show favourable safety. This study will help clinicians recommend/prescribe probiotics for specific symptoms.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30219 - Gastroenterology and hepatology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Alimentary Pharmacology & Therapeutics
ISSN
0269-2813
e-ISSN
—
Volume of the periodical
47
Issue of the periodical within the volume
8
Country of publishing house
GB - UNITED KINGDOM
Number of pages
17
Pages from-to
1054-1070
UT code for WoS article
000428308500001
EID of the result in the Scopus database
2-s2.0-85042149123